Somaxon (SOMX) Gets Silenor Guidance from FDA in OTC Development; Appoints New Sales SVP
Go back to Somaxon (SOMX) Gets Silenor Guidance from FDA in OTC Development; Appoints New Sales SVP| Procter & Gamble (NYSE: PG) | Delayed: 144.68 +1.71 (1.20%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $142.97 | 52 Week High | $90.33 | |||
| Open | $143.02 | 52 Week Low | $74.01 | |||
| Day High | $145.27 | P/E | 39.00 | |||
| Day Low | $142.14 | EPS | $3.71 | |||
| Volume | 10,271,076 | |||||
| SOMAXON PHARMA (NASDAQ: SOMX) | Delayed: 3.00 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.00 | 52 Week High | $3.17 | |||
| Open | $3.00 | 52 Week Low | $0.22 | |||
| Day High | $3.00 | P/E | N/A | |||
| Day Low | $3.00 | EPS | $-3.05 | |||
| Volume | 300 | |||||
